帕立骨化醇注射液联合盐酸西那卡塞片治疗维持性血液透析继发性甲状旁腺功能亢进患者的效果  

Effects of Paricalcitol injection combined with Cinacalcet hydrochloride tablets in treatment of maintenance hemodialysis patients with secondary hyperparathyroidism

作　　者：陈裕锋 CHEN Yufeng(Department of Nephrology of Taihe Shangu Hospital,Ji’an 343700 Jiangxi,China)

机构地区：[1]泰和山谷医院肾内科,江西吉安343700

出　　处：《中国民康医学》2024年第23期28-30,共3页Medical Journal of Chinese People’s Health

摘　　要：目的:观察帕立骨化醇注射液联合盐酸西那卡塞片治疗维持性血液透析(MHD)继发性甲状旁腺功能亢进(SHPT)患者的效果。方法:选取2022年1月至2023年1月该院收治的90例MHD SHPT患者进行前瞻性研究,按照随机数字表法将其分为研究组与对照组各45例。对照组给予盐酸西那卡塞片治疗,研究组在对照组基础上联合帕立骨化醇注射液治疗,比较两组临床疗效,治疗前后血磷水平、血清成纤维细胞生长因子23(FGF23)水平、血清全段甲状旁腺激素(iPTH)水平、甲状旁腺体积和不良反应发生率。结果:研究组治疗总有效率为93.33%,明显高于对照组的77.78%,差异有统计学意义(P<0.05);治疗后,两组血磷、血清FGF23、血清iPTH水平低于治疗前,且研究组低于对照组,两组甲状旁腺体积小于治疗前,且研究组小于对照组,差异均有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:帕立骨化醇注射液联合盐酸西那卡塞片治疗MHD SHPT患者可提高治疗总有效率,降低血磷、血清FGF23、血清iPTH水平,缩小甲状旁腺体积,效果优于单纯盐酸西那卡塞片治疗。Objective:To observe effects of Paricalcitol injection combined with Cinacalcet hydrochloride tablets in treatment of maintenance hemodialysis(MHD)patients with secondary hyperparathyroidism(SHPT).Methods:A prospective study was conducted on 90 MHD patients with SHPT admitted to the hospital from January 2022 to January 2023.According to the random number table method,they were divided into study group and control group,45 cases in each group.The control group was treated with Cinacalcet hydrochloride tablets,while the study group was treated with Paricalcitol injection on the basis of that of the control group.The clinical efficacy,the serum phosphorus level,the serum fibroblast growth factor 23(FGF23)level,the serum intact parathyroid hormone(iPTH)level,the parathyroid volume,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the study group was 93.33%,which was significantly higher than 77.78%of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of serum phosphorus,serum FGF23,serum iPTH in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and parathyroid volume in the two groups were smaller than those before the treatment,those in the study group was smaller than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Paricalcitol injection combined with Cinacalcet hydrochloride tablets in the treatment of the MHD patients with SHPT can improve the total effective rate of treatment,and reduce the serum phosphorus,serum FGF23,serum iPTH levels and the parathyroid volume.Moreover,it is superior to simple Cinacalcet hydrochloride tablets treatment.

关 键 词：维持性血液透析 继发性甲状旁腺功能亢进 帕立骨化醇 西那卡塞 血磷 成纤维细胞生长因子23 全段甲状旁腺激素 

分 类 号：R582.1[医药卫生—内分泌]